Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
Currently, the medication is being tested in phase 3 trials, and FDA approval may come as early as 2027
Adjusting your glucagon-like peptide-1 receptor (GLP-1) agonist dosage is a standard part of the weight loss journey, designed to help your body adapt to the medication while maximizing its benefits
For many patients, the 1.7 mg dose delivers meaningful appetite suppression and weight management effects, making dose reduction a viable compromise
It assisted in reducing liver fat, an important indicator for metabolic health, and alleviated symptoms such as knee pain and sleep apnea, which are typical among individuals with obesity
Cost and Accessibility: Currently, the production cost of peptide drugs is relatively high, but the long-acting properties of retasopeptide may reduce the frequency of medication and improve patient compliance
Starting semaglutide or tirzepatide now, then potentially transitioning to Retatrutide later, allows you to begin losing weight and improving health immediately
US$ 22.77
US$ 25.43
US$ 22.44
US$ 25.03
US$ 29.17
US$ 25.33
